ClinicalTrials.gg
CompletedNCT04016077Updated Apr 8, 2021Results posted

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

A Phase 1 interventional study of PF-06651600 30 mg in Hepatic Impairment and Healthy Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the effect of hepatic impairment on the pharmacokinetic(s) (PK) of PF-06651600 following administration of multiple once daily doses of PF-06651600. The safety and tolerability of PF-06651600 will also be evaluated in this study.

02

Conditions studied

  • Hepatic Impairment
  • Healthy Participants

Keywords

  • PF-06651600
  • Pharmacokinetics
  • Hepatic impairment
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations and other study procedures
  • (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb)

Additional Inclusion Criteria for Participants with Normal Hepatic Function:

  • Healthy male or female participants
  • No known or suspected hepatic disease

Additional Inclusion Criteria for Participants with Impaired Hepatic Function:

  • Stable hepatic impairment, defined as no change in disease status within the last 30 days prior to the Screening visit
  • No other ongoing clinically significant abnormalities based on medical history, physical examination, vital signs, 12-lead , and clinical laboratory tests except for the abnormal findings that are related to the participant's hepatic impairment.
  • Satisfy the criteria for Class A or Class B of the classification (mild: Child-Pugh Scores 5-6 points, and moderate: Child Pugh Scores 7-9 points), within 28 days of product administration.

Exclusion criteria

Exclusion Criteria:

  • Has active acute or chronic infection requiring treatment or history of systemic infection requiring hospitalization, incl. herpes zoster, herpes simplex, tuberculosis
  • Infection with , or
  • Any condition affecting drug absorption, distribution, metabolism and excretion (eg, status post porta-caval shunt surgery, prior bariatric surgery, gastrectomy, ileal resection)
  • Has , lymphoproliferative disorder, surgery or other condition not allowed per protocol

Additional Exclusion Criteria for Participants with Normal Hepatic Function:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, gynecologic or allergic disease

Additional Exclusion Criteria for Participants with Impaired Hepatic Function:

  • Has encephalopathy, severe ascites and/or pleural effusion, score >9 or medical conditions (like hepatorenal syndrome, gastrointestinal hemorrhage, etc.) excluded per protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    PF-06651600 Moderate Hepatic Impairment

    This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.

    Drug: PF-06651600 30 mg

  • Experimental
    PF-06651600 Healthy participants

    This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.

    Drug: PF-06651600 30 mg

  • Experimental
    PF-06651600 Mild Hepatic Impairment

    This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.

    Drug: PF-06651600 30 mg

Interventions

  • PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600

    AUC24 of PF-06651600 pre and post dose.

    Time frame: Hour 0 (pre-dose) on Days 7, 8 and 9, and hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24 hours post-dose on Day 10

  2. Maximum Plasma Concentration (Cmax) for PF-06651600

    Cmax is maximum observed plasma concentration.

    Time frame: Hour 0 (pre-dose) on Days 7, 8 and 9, and hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24 hours post-dose on Day 10

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)

    AEs with all causalities were any untoward medical occurrences in a study participant administered a product which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)

  2. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, leukocytes, neutrophils, prothrombin time, prothrombin intl. normalized ratio), chemistry (bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, sodium, potassium, calcium, bicarbonate and glucose), urinalysis (glucose, ketones, protein, hemoglobin, urobilinogen, bilirubin and nitrite). Each parameter was evaluated against commonly used and widely accepted criteria.

    Time frame: Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)

  3. Number of Participants With Out of Range Vital Signs

    Vital signs included supine blood pressure, pulse rate and temperature. The pre-specified out of range criterion for supine diastolic blood pressure was change from baseline equal to or over than (≥) 20 millimeter of mercury (mmHg). Clinical significance of vital signs and out of range criterion were determined at the investigator's discretion.

    Time frame: Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)

  4. Number of Adverse Events Leading to Discontinuation

    Adverse events result in participants discontinuations from the study drug.

    Time frame: Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)

07

Results

Posted Apr 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneModerate Hepatic ImpairmentNormal Hepatic Function
Started108
Completed108
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600

AUC24 of PF-06651600 pre and post dose.

Time frame:
Hour 0 (pre-dose) on Days 7, 8 and 9, and hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24 hours post-dose on Day 10
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600
nanogram*hour per milliliter (ng*hr/mL)Moderate Hepatic ImpairmentNormal Hepatic Function
Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600454.5 ± 45383.6 ± 16
Statistical analysis
  • Moderate Hepatic Impairment vs Normal Hepatic Function · ANOVA · Ratio of geometric means: 118.50 · 90% CI 87.96 to 159.64
PrimaryMaximum Plasma Concentration (Cmax) for PF-06651600

Cmax is maximum observed plasma concentration.

Time frame:
Hour 0 (pre-dose) on Days 7, 8 and 9, and hour 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24 hours post-dose on Day 10
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) for PF-06651600
nanogram per milliliter (ng/mL)Moderate Hepatic ImpairmentNormal Hepatic Function
Maximum Plasma Concentration (Cmax) for PF-06651600194.3 ± 49186.9 ± 24
Statistical analysis
  • Moderate Hepatic Impairment vs Normal Hepatic Function · ANOVA · Ratio of geometric means: 104.00 · 90% CI 74.48 to 145.23
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)

AEs with all causalities were any untoward medical occurrences in a study participant administered a product which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)
ParticipantsModerate Hepatic ImpairmentNormal Hepatic Function
AEs (all causalities)42
AEs (treatment related)41
SAEs (all causalities)10
SAEs (treatment related)10
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, leukocytes, neutrophils, prothrombin time, prothrombin intl. normalized ratio), chemistry (bilirubin, direct bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, sodium, potassium, calcium, bicarbonate and glucose), urinalysis (glucose, ketones, protein, hemoglobin, urobilinogen, bilirubin and nitrite). Each parameter was evaluated against commonly used and widely accepted criteria.

Time frame:
Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsModerate Hepatic ImpairmentNormal Hepatic Function
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)92
SecondaryNumber of Participants With Out of Range Vital Signs

Vital signs included supine blood pressure, pulse rate and temperature. The pre-specified out of range criterion for supine diastolic blood pressure was change from baseline equal to or over than (≥) 20 millimeter of mercury (mmHg). Clinical significance of vital signs and out of range criterion were determined at the investigator's discretion.

Time frame:
Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)
Reported as:
Count of participants · Participants
Number of Participants With Out of Range Vital Signs
ParticipantsModerate Hepatic ImpairmentNormal Hepatic Function
Number of Participants With Out of Range Vital Signs10
SecondaryNumber of Adverse Events Leading to Discontinuation

Adverse events result in participants discontinuations from the study drug.

Time frame:
Baseline (Day 0) up to 28 days after last dose of study medication (Day 39)
Reported as:
Number · adverse events
Number of Adverse Events Leading to Discontinuation
adverse eventsModerate Hepatic ImpairmentNormal Hepatic Function
Number of Adverse Events Leading to Discontinuation20

Adverse events

Collected over Baseline (Day 0) up to Day 39 (28 days after last dose of study medication).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Hepatic Impairment0/10 (0%)1/10 (10%)3/10 (30%)
Normal Hepatic Function0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent serious events
Most frequent serious events
EventModerate Hepatic ImpairmentNormal Hepatic Function
CholestasisHepatobiliary disorders1/100/8
Most frequent other events
Most frequent other events
EventModerate Hepatic ImpairmentNormal Hepatic Function
Arthropod biteInjury, poisoning and procedural complications0/101/8
HeadacheNervous system disorders1/101/8
ThrombocytopeniaBlood and lymphatic system disorders1/100/8
DiarrhoeaGastrointestinal disorders1/100/8
Hepatic enzyme increasedInvestigations1/100/8

Baseline characteristics

All 18 participants who were included in the study.

Age, Continuous
Age, Continuous(Years)Moderate Hepatic ImpairmentNormal Hepatic FunctionTotal
Mean59.0 ± 6.8857.4 ± 6.4858.3 ± 6.56
Sex: Female, Male
Sex: Female, Male(Participants)Moderate Hepatic ImpairmentNormal Hepatic FunctionTotal
Female347
Male7411
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Moderate Hepatic ImpairmentNormal Hepatic FunctionTotal
Hispanic or Latino7411
Not Hispanic or Latino246
Unknown or Not Reported101
08

Study locations

2 sites
  • University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Mar 2020, 7 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 11, 2019
StartActual
Jul 19, 2019
Primary completionActual
Mar 5, 2020
CompletionActual
Mar 5, 2020
Results first posted
Apr 8, 2021
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04016077
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 11, 2019
Start date
Jul 19, 2019
Primary completion
Mar 5, 2020
Completion
Mar 5, 2020
Results posted
Apr 8, 2021
Last update
Apr 8, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion